Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform ...
FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield (Reuters) -AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed ...
Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies “Engineered T cell therapies have demonstrated ...
SANTA MONICA, Calif. & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a preclinical stage biotechnology company pioneering a new class of fully individualized T cell receptor (TCR) therapies ...
Nov 29 (Reuters) - AstraZeneca AZN.L said on Tuesday it would acquire Neogene Therapeutics, a developer of cell-based cancer treatments, for up to $320 million, as the London-listed drugmaker seeks to ...
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of ...
AstraZeneca expanded its oncology portfolio Tuesday morning by announcing it reached an agreement to buy Neogene Therapeutics. The British pharma giant is purchasing the clinical-stage biotechnology ...
Raphaël Rousseau, M.D., Ph.D., is the latest biopharma vet to land at transatlantic biotech Neogene Therapeutics, where he joins a leadership bench of Kite and Bristol Myers Squibb veterans. Rousseau ...
NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback